글로벌 신경 바이오마커 시장 (2023-2030) : 알츠하이머병, 파킨슨병, 다발성 경화증, 자폐증

■ 영문 제목 : Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer’s, Parkinson’s, Multiple Sclerosis, Autism), By Type, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Grand View Research가 발행한 조사보고서이며, 코드는 GRV23NOV175 입니다.■ 상품코드 : GRV23NOV175
■ 조사/발행회사 : Grand View Research
■ 발행일 : 2023년 9월
■ 페이지수 : 120
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (납기:3일)
■ 조사대상 지역 : 세계
■ 산업 분야 : 임상 진단
■ 판매가격 / 옵션 (부가세 10% 별도)
Single User (1인 열람용)USD5,950 ⇒환산₩8,032,500견적의뢰/주문/질문
Multi User (5인 열람용)USD6,950 ⇒환산₩9,382,500견적의뢰/주문/질문
Global/corporate License (기업 열람용)USD8,950 ⇒환산₩12,082,500견적의뢰/구입/질문
가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
글로벌 신경 바이오마커 시장의 성장과 동향
Grand View Research사의 최신 보고서에 따르면, 세계의 신경 바이오마커 시장은 2022년까지 187억 5000만 달러에 달할 것으로 예상되며, 2023년부터 2030년까지 연평균 12. 8%의 성장률을 보일 것으로 예상됩니다. 신약 개발을 촉진하는 신경 바이오마커 연구개발에 대한 자금 지원 증가가 시장 성장을 견인할 것으로 보입니다. 미국 국립 신경질환 및 뇌졸중 연구소(National Institute of Neurological Disorders and Stroke)는 임상적 검증, 분석적 검증, 바이오마커 탐색과 관련된 연구를 수행하는 연구자들에게 공동연구 계약, 개발 보조금 등의 자금 지원 기회를 제공하고 있습니다.

바이오마커는 신경질환 치료제 개발에 중요한 역할을 합니다. 최근 신경질환 치료제 연구개발에 대한 투자가 크게 증가하고 있습니다. 예를 들어, 2020년 12월, 비영리 연구재단인 Target ALS는 ALS의 새로운 바이오마커 발견에 초점을 맞춘 프로젝트에 1,500만 달러의 연구 자금을 지원한다고 발표했습니다.

높은 S/N비를 가진 디지털화된 ELISA 테스트인 Quanterix Simoa(단일 분자 어레이)와 같은 기술적으로 진보된 제품을 사용할 수 있습니다. 이 기술은 신경 질환 관련 바이오마커와 관련된 혈액 뇌 장벽 문제를 극복하는 데 도움이 됩니다. 이러한 기술 발전은 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2021년 1월 애보트는 뇌진탕을 포함한 외상성 뇌손상에 대한 최초의 신속 혈액 검사를 발표했습니다. 이 검사는 외상성 뇌 손상 후 혈액에서 검출되는 특정 단백질을 측정하는 것으로, 검사 결과가 음성인 경우 CT 스캔의 필요성을 배제하는 데 사용할 수 있습니다.

특히 개발도상국이나 저개발 국가에서는 이러한 진단 제품에 대한 인식 부족, 높은 비용, 신경과 의사의 가용성 제한 및 부재와 같은 요인이 이러한 바이오마커 기반 진단 솔루션의 채택에 영향을 미칠 수 있습니다. 세계신경과학연맹(World Federation of Neurology)이 세계보건기구(WHO) 회원국 63/84개국을 대상으로 실시한 조사에 따르면, 31/63개국의 신경과 의사 대다수가 대도시에 근무하고 있으며, 신경과 의사 1명이 약 6,240~4,750,000명의 인구를 진료하고 있는 것으로 나타났습니다.

신경 바이오마커 시장 보고서 주요 내용

- 2022년에는 프로테오믹스 유형이 가장 큰 시장 점유율을 차지할 것으로 예상되며, 예측 기간 동안에도 그 우위를 유지할 것으로 전망됩니다.

- 파킨슨병 분야는 유병률 증가와 연구개발 활동의 증가로 인해 가장 큰 시장 점유율을 차지할 것으로 보입니다.

- 최종 용도별로는 연구기관 및 기타 부문이 신경 바이오마커 시장을 지배했습니다. 신경 질환 치료제 개발을 위해 공동 연구를 수행하는 연구 기관은 약물 내성을 평가하기 위해 바이오마커를 활용하고 있습니다.

- 북미는 미국과 캐나다에서 강력한 입지를 가진 시장 플레이어의 존재와 새로운 바이오마커 개발을 위한 정부 자금의 증가로 인해 시장을 지배하고 있습니다.

- 아시아 태평양 지역은 일본과 호주와 같은 선진국에서 기술적으로 진보된 진단 제품의 채택이 증가하고, 중국과 인도와 같은 개발도상국에서 이러한 제품의 채택이 증가함에 따라 예측 기간 동안 큰 성장이 예상됩니다.
■ 보고서 개요

Chapter 1. 조사 방법 및 범위
Chapter 2. 개요
Chapter 3. 시장 변동, 동향, 범위
Chapter 4. 세계의 신경 바이오마커 시장 : 유형별 예측 및 동향 분석
Chapter 5. 세계의 신경 바이오마커 시장 : 용도별 예측 및 동향 분석
Chapter 6. 세계의 신경 바이오마커 시장 : 최종 용도별 예측 및 동향 분석
Chapter 7. 세계의 신경 바이오마커 시장 : 지역별 예측 및 동향 분석
Chapter 8. 경쟁 분석

■ 보고서 목차

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definition
1.1.1.1 Application Segment
1.1.1.2 Type Segment
1.1.1.3 End Use Segment
1.2 Regional Scope
1.3 Estimates and Forecast Timeline
1.4 Objectives
1.4.1 Objective – 1
1.4.2 Objective – 2
1.4.3 Objective – 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Gvr’s Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information Or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List of Secondary Sources
1.11 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Application and Type Snapshot
2.3 End Use Snapshot
2.4 Competitive Landscape Snapshot
Chapter 3 Neurological Biomarkers Market Variables, Trends, and Scope
3.1 Neurological Biomarkers Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration And Growth Prospect Mapping
3.3 Pipeline Analysis
3.3.1 Alzheimer’s Disease
3.3.2 Parkinson’s Disease
3.3.3 Multiple Sclerosis
3.3.4 Autism Spectrum Disorder
3.4 Market Dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Increasing Prevalence Of Neurological Diseases
3.4.1.2 Technological Advancements
3.4.1.3 Increased Funding For R&D In Biomarkers
3.4.2 Market Restraint Analysis
3.4.2.1 Lack Of Consumer Awareness
3.4.2.2 Reimbursement Policies
3.5 Neurological Biomarkers: Market Analysis Tools
3.5.1 Industry Analysis – Porter’s
3.5.2 Pestle Analysis
Chapter 4 Neurological Biomarkers Market: Segment Analysis, By Type, 2018 – 2030 (USD Million)
4.1 Neurological Biomarkers Market: Type Movement Analysis
4.1.1 Genomic
4.1.1.1 Genomic Neurological Biomarkers Market, 2018 – 2030 (USD Million)
4.1.2 Proteomic
4.1.2.1 Proteomic Neurological Biomarkers Market, 2018 – 2030 (USD Million)
4.1.3 Metabolomic
4.1.3.1 Metabolomic Neurological Biomarkers Market, 2018 – 2030 (USD Million)
4.1.4 Imaging
4.1.4.1 Imaging Neurological Biomarkers Market, 2018-2030 (USD Million)
4.1.5 Others
4.1.5.1 Others Neurological Biomarkers Market, 2018 – 2030 (USD Million)
Chapter 5 Neurological Biomarkers Market: Segment Analysis, By Application, 2018 – 2030 (USD Million)
5.1 Neurological Biomarkers Market: Application Movement Analysis
5.1.1 Alzheimer’s Disease
5.1.1.1 Alzheimer’s Disease Market, 2018 – 2030 (USD Million)
5.1.2 Parkinson’s Disease
5.1.2.1 Parkinson’s Disease Market, 2018 – 2030 (USD Million)
5.1.3 Multiple Sclerosis
5.1.3.1 Multiple Sclerosis Market, 2018 – 2030 (USD Million)
5.1.4 Autism Spectrum Disorder
5.1.4.1 Autism Spectrum Disorder Market, 2018 – 2030 (USD Million)
5.1.5 Others
5.1.5.1 Others Market, 2018 – 2030 (USD Million)
Chapter 6 Neurological Biomarkers Market: Segment Analysis, By End Use, 2018 – 2030 (USD Million)
6.1 Neurological Biomarkers Market: End Use Movement Analysis
6.1.1 Hospital & Hospital Laboratories
6.1.1.1 Hospitals & Hospital Laboratories Market, 2018 – 2030 (USD Million)
6.1.2 Independent Clinical Diagnostic Centers
6.1.2.1 Independent Clinical Diagnostic Centers Market, 2018 – 2030 (USD Million)
6.1.3 Research Organizations And Others
6.1.3.1 Research Organizations and Others Market, 2018 – 2030 (USD Million)
Chapter 7 Neurological Biomarkers Market: Segment Analysis, By Region, 2018 – 2030 (USD Million)
7.1 Regional Market Snapshot
7.2 North America
7.2.1 North America Neurological Biomarkers Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.2.2.2 Key Country Dynamics
7.2.2.3 Regulatory Framework
7.2.2.4 Reimbursement Scenario
7.2.3 Canada
7.2.3.1 Canada Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.2.3.2 Key Country Dynamics
7.2.3.3 Regulatory Framework
7.2.3.4 Reimbursement Scenario
7.3 Europe
7.3.1 Europe Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.3.2 UK
7.3.2.1 UK Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.3.2.2 Key Country Dynamics
7.3.2.3 Regulatory Framework
7.3.2.4 Reimbursement Scenario
7.3.3 Germany
7.3.3.1 Germany Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.3.3.2 Key Country Dynamics
7.3.3.3 Regulatory Framework
7.3.3.4 Reimbursement Scenario
7.3.4 Spain
7.3.4.1 Spain Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.3.4.2 Key Country Dynamics
7.3.4.3 Regulatory Framework
7.3.4.4 Reimbursement Scenario
7.3.5 France
7.3.5.1 France Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.3.5.2 Key Country Dynamics
7.3.5.3 Regulatory Framework
7.3.5.4 Reimbursement Scenario
7.3.6 Italy
7.3.6.1 Italy Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.3.6.2 Key Country Dynamics
7.3.6.3 Regulatory Framework
7.3.6.4 Reimbursement Scenario
7.3.7 Denmark
7.3.7.1 Denmark Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.3.7.2 Key Country Dynamics
7.3.7.3 Regulatory Framework
7.3.7.4 Reimbursement Scenario
7.3.8 Sweden
7.3.8.1 Sweden Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.3.8.2 Key Country Dynamics
7.3.8.3 Regulatory Framework
7.3.8.4 Reimbursement Scenario
7.3.9 Norway
7.3.9.1 Norway Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.3.9.2 Key Country Dynamics
7.3.9.3 Regulatory Framework
7.3.9.4 Reimbursement Scenario
7.4 Asia Pacific
7.4.1 Asia-Pacific Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.4.2 Japan
7.4.2.1 Japan Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.4.2.2 Key Country Dynamics
7.4.2.3 Regulatory Framework
7.4.2.4 Reimbursement Scenario
7.4.3 China
7.4.3.1 China Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.4.3.2 Key Country Dynamics
7.4.3.3 Regulatory Framework
7.4.3.4 Reimbursement Scenario
7.4.4 India
7.4.4.1 India Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.4.4.2 Key Country Dynamics
7.4.4.3 Regulatory Framework
7.4.4.4 Reimbursement Scenario
7.4.5 South Korea
7.4.5.1 South Korea Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.4.5.2 Key Country Dynamics
7.4.5.3 Regulatory Framework
7.4.5.4 Reimbursement Scenario
7.4.6 Thailand
7.4.6.1 Thailand Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.4.6.2 Key Country Dynamics
7.4.6.3 Regulatory Framework
7.4.6.4 Reimbursement Scenario
7.4.7 Australia
7.4.7.1 Australia Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.4.7.2 Key Country Dynamics
7.4.7.3 Regulatory Framework
7.4.7.4 Reimbursement Scenario
7.5 Latin America
7.5.1 Latin America Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.5.2.2 Key Country Dynamics
7.5.2.3 Regulatory Framework
7.5.2.4 Reimbursement Scenario
7.5.3 Mexico
7.5.3.1 Mexico Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.5.3.2 Key Country Dynamics
7.5.3.3 Regulatory Framework
7.5.2.4 Reimbursement Scenario
7.5.4 Argentina
7.5.4.1 Argentina Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.5.4.2 Key Country Dynamics
7.5.4.3 Regulatory Framework
7.5.4.4 Reimbursement Scenario
7.6 MEA
7.6.1 MEA Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.6.2.2 Key Country Dynamics
7.6.2.3 Regulatory Framework
7.6.2.4 Reimbursement Scenario
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.6.3.2 Key Country Dynamics
7.6.3.3 Regulatory Framework
7.6.3.4 Reimbursement Scenario
7.6.4 UAE
7.6.4.1 UAE Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.6.4.2 Key Country Dynamics
7.6.4.3 Regulatory Framework
7.6.2.4 Reimbursement Scenario
7.6.5 Kuwait
7.6.5.1 Kuwait Neurological Biomarkers Market, 2018 – 2030 (USD Million)
7.6.5.2 Key Country Dynamics
7.6.5.3 Regulatory Framework
7.6.5.4 Reimbursement Scenario
Chapter 8 Neurological Biomarkers Market: Competitive Analysis
8.1 Company Categorization
8.2 Strategy Mapping
8.2.1 New product launch
8.2.2 Partnerships
8.2.3 Acquisition
8.2.4 Collaboration
8.2.5 Funding
8.3 Company Market Share Analysis, 2022
8.4 Company Profiles
8.4.1 ABBOTT
8.4.1.1 Company overview
8.4.1.2 Financial performance
8.4.1.3 Product benchmarking
8.4.1.4 Strategic initiatives
8.4.2 JOHNSON & JOHNSON SERVICES, INC.
8.4.2.1 Company overview
8.4.2.2 Financial performance
8.4.2.3 Product benchmarking
8.4.2.4 Strategic initiatives
8.4.3 BIO-RAD LABORATORIES, INC.
8.4.3.1 Company overview
8.4.3.2 Financial performance
8.4.3.3 Product benchmarking
8.4.3.4 Strategic initiatives
8.4.4 ALSERES PHARMACEUTICALS, INC.
8.4.4.1 Company overview
8.4.4.2 Product benchmarking
*Pipeline candidate
8.4.5 BANYAN BIOMARKERS, INC.
8.4.5.1 Company overview
8.4.5.2 Product benchmarking
8.4.5.3 Strategic initiatives
8.4.6 RULES-BASED MEDICINE
8.4.6.1 Company overview
8.4.6.2 Financial performance
8.4.6.3 Product benchmarking
8.4.6.4 Strategic initiatives
8.4.7 THERMO FISHER SCIENTIFIC, INC.
8.4.7.1 Company overview
8.4.7.2 Financial performance
8.4.7.3 Product benchmarking
8.4.7.4 Strategic initiatives
8.4.8 DIAGENIC ASA
8.4.8.1 Company overview
8.4.8.2 Product benchmarking
8.4.9 MERCK & CO., INC.
8.4.9.1 Company overview
8.4.9.2 Financial performance
8.4.9.3 Product benchmarking
8.4.9.4 Strategic initiatives
8.4.10 QUANTERIX
8.4.10.1 Company overview
8.4.10.2 Product benchmarking
8.4.10.3 Strategic initiatives

List of Tables

Table 1 List of Abbreviation
Table 2 North America neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 3 North America neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 4 North America neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 5 U.S. neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 6 U.S. neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 7 U.S. neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 8 Canada neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 9 Canada neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 10 Canada neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 11 Europe neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 12 Europe neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 13 Europe neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 14 U.K. neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 15 U.K. neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 16 U.K. neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 17 Germany neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 18 Germany neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 19 Germany neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 20 France neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 21 France neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 22 France neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 23 Italy neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 24 Italy neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 25 Italy neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 26 Spain neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 27 Spain neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 28 Spain neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 29 Denmark neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 30 Denmark neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 31 Denmark neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 32 Sweden neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 33 Sweden neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 34 Sweden neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 35 Norway neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 36 Norway neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 37 Norway neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 38 Asia Pacific neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 39 Asia Pacific neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 40 Asia Pacific neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 41 Japan neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 42 Japan neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 43 Japan neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 44 China neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 45 China neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 46 China neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 47 India neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 48 India neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 49 India neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 50 South Korea neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 51 South Korea neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 52 South Korea neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 53 Australia neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 54 Australia neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 55 Australia neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 56 Thailand neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 57 Thailand neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 58 Thailand neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 59 Latin America neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 60 Latin America neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 61 Latin America neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 62 Brazil neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 63 Brazil neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 64 Brazil neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 65 Mexico neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 66 Mexico neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 67 Mexico neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 68 Argentina neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 69 Argentina neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 70 Argentina neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 71 MEA neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 72 MEA neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 73 MEA neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 74 South Africa neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 75 South Africa neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 76 South Africa neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 77 Saudi Arabia neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 78 Saudi Arabia neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 79 Saudi Arabia neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 80 UAE neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 81 UAE neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 82 UAE neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
Table 83 Kuwait neurological biomarkers market, by application, 2018 - 2030 (USD Million)
Table 84 Kuwait neurological biomarkers market, by type, 2018 - 2030 (USD Million)
Table 85 Kuwait neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
※본 조사보고서 [글로벌 신경 바이오마커 시장 (2023-2030) : 알츠하이머병, 파킨슨병, 다발성 경화증, 자폐증] (코드 : GRV23NOV175) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [글로벌 신경 바이오마커 시장 (2023-2030) : 알츠하이머병, 파킨슨병, 다발성 경화증, 자폐증] 에 대해서 E메일 문의는 여기를 클릭하세요.
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!